We Offer Worldwide Shipping
Login Wishlist

Deoxycholic Acid

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-P0297

  • Specification : 98.0%(HPLC)

  • CAS number : 83-44-3

  • PUBCHEM ID : 222528

  • Volume : 100mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0297

Analysis Method

HPLC,NMR,MS

Specification

98.0%(HPLC)

Storage

2-8°C

Molecular Weight

Appearance

White crystalline powder

Botanical Source

Structure Type

Quinolines/Isoquinolines

Category

Standards;Natural Pytochemical;API

SMILES

CC(CCC(=O)O)C1CCC2C1(C(CC3C2CCC4C3(CCC(C4)O)C)O)C

Synonyms

7-DEOXYCHOLIC ACID/Cholan-24-oic acid, 3,12-dihydroxy-, (3α,5β,12α)-/5b-Deoxycholic acid/Deoxycholatic acid/Deoxycholic acid/17b-(1-Methyl-3-carboxypropyl)etiocholane-3a,12a-diol/deoxy-Cholic acid/(3α,5β,12α)-3,12-Dihydroxycholan-24-oic acid/7α-Deoxycholic acid/Kybella/3α,12α-dihydroxy-5β-cholan-24-oic acid/ATX-101/5b-Cholanic acid-3a,12a-diol/Dihydroxycholanoic acid/Cholic acid, deoxy-/(3a,5b,12a)-3,12-Dihydroxy-5-cholan-24-oic Acid/(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-Dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

IUPAC Name

(4R)-4-[(3R,5R,8R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

Applications

Deoxycholic acid is specifically responsible for activating the G protein-coupled bile acid receptor TGR5 that stimulates brown adipose tissue (BAT) thermogenic activity.

Density

1.1±0.1 g/cm3

Solubility

Methanol; Dichloromethane

Flash Point

298.8±22.4 °C

Boiling Point

547.1±35.0 °C at 760 mmHg

Melting Point

171-174 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2918190000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:83-44-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28244904

Title

Deoxycholic Acid.

Author

Rose PT1.

Publish date

2017 Apr

PMID

29016540

Title

Deoxycholic Acid Injections for Bra-Line Lipolysis.

Author

Jegasothy SM1.

Publish date

2018 May

PMID

31977503

Abstract

BACKGROUND:
Injectable deoxycholic acid (DCA) may be used to remove excess submental fat and off-label for local adipose reduction. Despite DCA’s widespread use, rare incidences of severe, systemic, long-term adverse events (AEs) have been reported.

OBJECTIVE:
To evaluate the potential side effects associated with injectable DCA.

METHODS AND MATERIALS:
A systematic review was conducted using PubMed, Cochrane, CINAHL, and Web of Science using PRISMA guidelines to gather the literature relating to DCA or deoxycholate-associated AEs and their management.

RESULTS:
Twenty-eight manuscripts were included after full article review. Most commonly, patients experienced mild localized AEs, whereas a small number of patients experienced severe pain, alopecia, nasopharyngitis, dysphagia, dizziness/lightheadedness, and gastrointestinal upset. Severe, long-term AEs were reported as rare in the evaluated literature. Deoxycholic acid injections in large volumes were more likely to cause severe adverse effects.

CONCLUSION:
Self-resolving, mild side effects and severe but rare adverse effects have been reported with DCA use making it a safe treatment for local adipose reduction. Further studies are necessary to determine its safety profile, especially when using DCA in off-label areas.

Title

Adverse Events of Injectable Deoxycholic Acid.

Author

Pham CT1,2, Lee A3, Sung CT2, Choi F2, Juhasz M2, Mesinkovska NA2.

Publish date

2020 Jan 17